Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.

Abstract

Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin.

• Authors: Joanne M Donovan, Melissa Plone, Rafif Dagher, Mark Bree, Judith Marquis
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1054 Pg. 492-4 ( 2005) ISSN: 0077-8923 [Print] United States
• PMID: 16339704 (Publication Type: Journal Article, Review)

Chemical References

• 4'-hydroxydesazadesferrithiocin
• Carboxylic Acids
• Iron Chelating Agents
• Thiazoles
• Iron

Topics

• Administration, Oral
• Animals
• Carboxylic Acids (administration & dosage, pharmacokinetics, therapeutic use, toxicity)
• Chelation Therapy
• Clinical Trials, Phase I as Topic
• Dogs
• Drug Evaluation, Preclinical
• Feces (chemistry)
• Humans
• Iron (metabolism)
• Iron Chelating Agents (administration & dosage, pharmacokinetics, therapeutic use, toxicity)
• Iron Overload (drug therapy, etiology)
• Macaca fascicularis
• Molecular Structure
• Rats
• Thiazoles (administration & dosage, pharmacokinetics, therapeutic use, toxicity)
• beta-Thalassemia (complications, drug therapy)